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Abstract: The International Association for the Study of Lung
Cancer, (IASLC) International Congress on Advances in Pulmonary
Neuroendocrine Tumors was a two-day meeting held at the Royal
Brompton Hospital in London, United Kingdom on the thirteenth
and forteenth of December 2007. The meeting was led by 14
member international faculty—in the disciplines of pathology, sur-
gery, medicine, oncology, endocrinology, nuclear medicine, diag-
nostic imaging, and biostatistics. The aims were twofold, as an
educational meeting, and to develop the IASLC International Pul-
monary Neuroendocrine Tumors Registry. The meeting highlighted
the difference in presentation of the tumors, management options for
early and advanced stage disease including the use of novel agents
and approaches. The need, process, and approach to an International
Registry of Pulmonary Neuroendocrine Tumors were emphasized.
International collaboration to develop a retrospective registry, pro-
spective data collection, virtual tissue bank, and collaborative clin-
ical trials were universally agreed as the best way to advance our
understanding and treatment of these rare tumors.
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TYPICAL AND ATYPICAL CARCINOID
TUMORS–ANDREW NICHOLSON
Approximately 1 to 2% of lung tumors are typical and
atypical carcinoids. They occur equally in both genders. Be-
tween the two tumors, typical carcinoids account for the major-
ity with atypical carcinoids making up 11 to 24% of all pulmo-
nary carcinoids. Typical carcinoids classically show organoid
and/or trabecular architectures with mildly pleomorphic cells
comprising nuclei with granular chromatin and indistinct nucle-
oli and moderate volumes of eosinophilic cytoplasm. Architec-
ture may rarely be paraganglioid, clear cell, spindle cell, or
melaninocytic. Mitoses are less than two per 2 mm2 and there is
no necrosis. The classic immunohistochemical markers for car-
cinoid tumors are chromogranin A, synaptophysin, and CD56
(most sensitive). Atypical carcinoids are distinguished from
typical carcinoids by the presence of necrosis (typically small
foci within islands of cells) and/or the presence of 2 to 10
mitoses per 2 mm2. Atypical carcinoids may also show greater
architectural disorganization and increased pleomorphism, but
these are not discriminatory criteria. Regional and distant me-
tastases are more common in atypical carcinoids, but may rarely
also be seen in typical variants.1 Typical carcinoids arise some-
times on a background of diffuse idiopathic neuroendocrine cell
hyperplasia (DIPNECH), especially when peripheral in location,
and DIPNECH is regarded as preneoplastic in this context.
Recently, cases of atypical carcinoids and large cell neuroendo-
crine carcinoma (unpublished data) have also been shown to
arise in association with DIPNECH.2 Given that TTF-1 positiv-
ity, spindle cell morphology, and association with DIPNECH
are more commonly seen in peripheral carcinoids,3 it may be
that peripheral carcinoids are histogenetically different from
central carcinoids although this requires further investigation.
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LARGE CELL NEUROENDOCRINE
CARCINOMA AND SMALL CELL CARCINOMA–
WILLIAM D. TRAVIS
Large cell neuroendocrine carcinoma (LCNEC) and
small cell lung carcinomas (SCLC) are the two high grade
tumors in the neuroendocrine spectrum. LCNEC and SCLC
comprise 3% and 15 to 20%, respectively, of all invasive lung
cancers. There are no recognized preinvasive lesions for
either tumor in contrast to diffuse idiopathic pulmonary
neuroendocrine cell hyperplasia which is a rare preinvasive
lesion for carcinoids. The diagnostic criteria for LCNEC
include a neuroendocrine morphology with organoid nesting,
trabecular and rosette-like patterns, increased mitoses (11 or
more per high powered field or 2 mm2), features of nonsmall
cell carcinoma and neuroendocrine differentiation by electron
microscopy or immunohistochemistry. Approximately 80%
of LCNEC are pure and 20% are combined LCNEC with
other histologies such as adenocarcinoma or squamous car-
cinoma. Rossi et al.4 found the following percentage of
immunohistochemical expression in LCNEC for chromo-
granin A (65%), synaptophysin (53%), and CD56 (93%). The
diagnostic criteria for LCNEC, large cell with neuroendo-
crine morphology, large cell carcinoma with neuroendocrine
differentiation and large cell carcinoma (with no neuroendo-
crine features) are presented in Table 1. Neuroendocrine
differentiation can be seen in 10 to 20% of nonsmall cell lung
cancers (mostly adenocarcinoma), and the conflicting reports
of the influence on survival and response to chemotherapy
was highlighted.1
Up to two thirds of surgically resected SCLC are pure
SCLC and the remaining are combined SCLC with other
histologies such as adenocarcinoma, squamous carcinoma, or
large cell carcinoma (Table 2). In addition to the three
standard immunohistochemical markers, other highlighted
markers were AE1/AE3, Ki-67, neuron specific enolase, Bomb-
esin-like peptides PGP 9.5, and neuroendocrine-specific pro-
tein A and C. The difficulties of establishing a pathologic
diagnosis because of crush artifacts were emphasized and
sputum cytology suggested as a potential alternative. Similar
survival is reported in patients with LCNEC and SCLC.
Patients with SCLC and LCNEC are typically in the seventh
decade of life. SCLC patients may be slightly older and there is
a male predominance. The utility of mRNA gene expression
profiling (Affymetrix U133A) in the classification of neuroen-
docrine tumors were presented. The differences in the manage-
ment of SCLC (Surgery–controversial, Chemotherapy–pri-
mary approach, Radiation– effective locally) and LCNEC
(Surgery–if resectable, Chemotherapy–Probably needed,
Radiation– effective locally) were presented.
CLINICAL PRESENTATION–JAMES R. JETT
The epidemiology of carcinoid tumors was presented as
an annual rate in the SEER database (0.52 per 100,000 men,
0.89 per 100,000 women) and the Swedish registries (0.2 per
100,000 men, 1.3 per 100,000 women). The average age of
presentation of patients with typical carcinoid tumors is 45 to
50 years, and 10 years older for patients with atypical carci-
noid tumors. Typical carcinoid tumors are approximately four
times more common than atypical. The uncertain relationship
with smoking was emphasized. Approximately 75% of pa-
tients with carcinoid tumors present with central tumors, with
symptoms of cough, hemoptysis, wheeze, recurrent pneumo-
nia or chest pain in 52%. Ectopic hormone production resulting
in carcinoid syndrome (1–5%), Cushing syndrome (1–2%), and
acromegaly are rare. The utility of positron emission tomog-
raphy (PET) was highlighted in a series of 16 patients with
typical and atypical carcinoid tumors,5 that reported PET
positivity in 75% (not associated with any differences in
tumor size).
PARANEOPLASTIC SYNDROMES–PIERO FEROLLA
Paraneoplastic syndromes are by definition, disorders
that may accompany benign or malignant tumors but are not
TABLE 2. Histopathologic Differences Between SCLC and
LCNEC/LCCa
Feature SCLC LCNEC/LCC
Cell size Smaller ( 3 small
resting lymphocytes)
Larger
N/C ratio Higher Lower
Nuclear chromatin Finely granular, uniform Coarsely granular,
vesicular, less
uniform
Nucleoli Absent or faint Often (not always)
present, may be
prominent or faint
Nuclear molding Characteristic Uncharacteristic
Fusiform shape Common Uncommon
Polygonal shape with
ample pink cytoplasm
Uncharacteristic Characteristic
Nuclear smear Common Uncommon
Basophilic staining of
stroma and vessels
Occasional Rare
a Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung
with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural,
immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol
1991;15:529–553.
TABLE 1. Spectrum of Neuroendocrine Differentiation in
Large Cell Carcinomasa
Diagnosis
Neuroendocrine
Morphology
Neuroendocrine Features
On Immunohistochemistry
or Electron Microscopy
Large cell neuroendocrine
carcinoma
Yes Yes
Large cell carcinoma with
neuroendocrine
morphology
Yes No
Large cell carcinoma with
neuroendocrine
differentiation
No Yes
Large cell carcinoma with
no neuroendocrine
features
No No
a From reference: Travis WD, Krug LM, Rusch V. Large cell neuroendocrine
carcinoma. In D Raghavan, ML Brecher, DH Johnson, et al. (Eds.), Textbook of
Uncommon Cancer. Chichester, West Sussex, England: John Wiley, 2006. Pp. 298–
306.
Journal of Thoracic Oncology • Volume 3, Number 10, October 2008 Proceedings of the IASLC International Workshop
Copyright © 2008 by the International Association for the Study of Lung Cancer 1195
directly related to mass effects or invasion by the primary
tumor or its metastases. They can be divided as hematolog-
ical, neurologic, dermatologic, and hormonal.
The molecular mechanisms underlying paraneoplastic
syndromes are incompletely understood. Genetic rearrange-
ments are rare although cellular dedifferentiation or dysdiffer-
entiation are more common in poorly differentiated neuroendo-
crine tumors, such as small cell and large cell neuroendocrine
carcinomas. Other abnormalities may include alterations in
transcriptional repression, changes in DNA methylation and
other factors that govern cell differentiation.
In the experience of the University of Perugia (Ferolla
et al., submitted), when an accurate endocrinological evalu-
ation is performed in the preoperative period in patients with
bronchial carcinoid, up to 15% have either clinical or sub-
clinical hypersecretion. A wide spectrum of hormones can be
secreted from both well differentiated (carcinoid) and poorly
differentiated lung neuroendocrine tumors (including ACTH,
CRH, GHRH, ADH, serotonin, histamine, gastrin, calcitonin,
takykinins, CgA, -HCG, NSE, bombesin, PTH, PTHrp,
IGF1, IGF2, and others). The nonspecific serum neuroendo-
crine marker Chromogranin A is currently considered the
most useful marker of well differentiated lung neuroendo-
crine tumors, although it is not associated with specific
symptoms and an association with prognosis is not yet deter-
mined. A linear correlation has been demonstrated between
nonspecific circulating neuroendocrine markers and the de-
velopment of complications. For example, serotonin levels
correlate with progression of heart valve and carcinoid heart
disease,6 and may be increased by cell lysis from the admin-
istration of chemotherapy.7
Thoracic neuroendocrine tumors (small cell lung carci-
noma, bronchial carcinoid and thymic carcinoids/carcinomas
in order of frequency) are the most common causes of ectopic
ACTH production.8 Unusual clinical presentations such as
“cyclical” Cushing syndrome have been reported.9 In a large
series of patients with SCLC, 1.6% of the total were reported
to have ectopic ACTH production.10 One or more features of
Cushing syndrome were observed in 57%, but the entire
spectrum of the symptoms is rare. All patients present with
hypokalemia and as type II diabetes develops, infections
become the principal cause of morbidity and mortality.
Bronchial carcinoid tumors are the most frequent cause
of ectopic acromegaly. The immunohistochemical demonstra-
tion of GHRH in the tumor cells and elevated plasma GHRH are
crucial for the diagnosis as GH and IGF1 levels (both basal or
after provocative tests) do not differentiate ectopic from eutopic
secretion. Often tumor hypersecretion is multihormonal. Ec-
topic GH secretion without concomitant GHRH hypersecre-
tion has been demonstrated only in a single case.11
Lung neuroendocrine tumors (mainly SCLC) are impor-
tant causes of inappropriate ADH secretion (SIADH). Clinical
features are indistinguishable from nonparaneoplastic causes
and include hyponatremia with corresponding hypo-osmola-
lity of serum and extracellular fluid. Compensatory mecha-
nisms, such as decreased thirst, aldosterone suppression, and
production of atrial natriuretic peptide, may mitigate the
development of hyponatremia.
When single or multiple hormone hypersecretion is
found in patients with neuroendocrine tumors, the association
of multiple endocrine neoplasia type 1 (MEN1) should be
borne in mind, as it is associated with significant mortality.
The most appropriate timing and modality for imaging and
hormonal follow-up for thoracic neuroendocrine tumors with
MEN1 is still a matter of debate.
NOVEL IMAGING TECHNIQUES–JAMSHED
BOMANJI
The indications for imaging are usually to characterize
the primary and screen for metastases. This can be achieved
by conventional x-ray, CT, MRI, receptor scintigraphy (e.g.,
111In-Pentetreotide) and PET (68Ga DOTATATE, 18F-FDG
PET/CT). High resolution CT gives information such as size,
position, density, calcification, edge configuration, and vas-
cularity. MRI generally provides information similar to that
of CT. There are a large number of radiopharmaceuticals
available for imaging (Table 3). There is marked variation in
affinity for 111In-pentetreotide, 123I-MIBG, and 18F-FDG. For
lung carcinoids, and in the author’s opinion, the 68Ga
DOTATATE PET tracer should be the imaging modality of
choice although it may not be widely available. Extensive
experience is now being obtained using DOTA-DPhe1,Tyr3-
octreotate (DOTATATE) (a SSR-2 analogue), radio-labeled
to 68Ga a positron emitter at the University College Hospital
in London. 68Ga DOTATATE typically shows uptake in
well-differentiated neuroendocrine tumors, with reduced sen-
sitivity in poorly differentiated tumors. It is best used to
delineate primary tumor and secondary inflammatory reac-
tions. In general, primary and well-differentiated neuroendo-
crine tumors show higher affinity for 68Ga DOTATATE and
metastatic and poorly differentiated tumors have a higher
affinity for 18F-FDG. 68Ga DOTATATE is emerging as an
important tracer for preoperative surgical planning and stag-
ing for recurrent disease possibly in combination with other
imaging modalities.
SURGERY FOR TYPICAL AND ATYPICAL
CARCINOIDS–VALERIE W. RUSCH
Surgical series from 1985 to 2006 report the postsur-
gery 5 year survival ranging from 92 to 100% for patients
with typical carcinoid tumors and 69 to 78% for patients with
atypical carcinoid tumors. The factors influencing prognosis
TABLE 3. Radiopharmaceuticals Available for Imaging
Radiopharmaceutical Mechanism of Action
I-123 MIBG Neuronal uptake I and II system
In-111 octreotide Somatostatin receptor (SSR 2)
binding and internalisation
F-18 FDG GLUT 1 system
Ga-68 peptides (DOTATATE) Somatostatin receptor (SSR 2)
binding and internalisation
C-11–5-hydroxytryptophane
C-11-L-DOPA
C-11 methionine
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include histologic subtype, nodal metastasis (especially for
atypical carcinoid tumors), ability to achieve complete resec-
tion and age. Data from 378 patients in the MSKCC neuroen-
docrine database from 1992 to 2007 were presented, illustrat-
ing similarities and differences in patient demographics, stage
and the excellent survival in patients with typical carcinoid
tumors, and intermediate survival in patients with atypical
carcinoid tumors. Postsurgical recurrence rates ranged be-
tween approximately 5 to 30%, with recurrence in distal sites
approximately four- to five-fold more common than local
recurrence.
SURGERY FOR LARGE CELL NEUROENDOCRINE
CARCINOMA–HISAO ASAMURA
From 1981 to 2006, the National Cancer Centre in
Tokyo operated on 159 patients with large cell neuroendo-
crine carcinoma. The median age of the cohort was 67 years,
with 89% men. Complete resection was achieved in 92%,
with the percentages in pathologic stage I to IV as 53, 18, 28,
and 2%, respectively. In total, 46 patients experienced distant
recurrence and 21 patients had local recurrences. The overall
5-year survival was 46%. Patients with resected LCNEC had
a poorer survival compared with other NSCLCs with patho-
logic stage I and the overall survival was similar to that of
small cell lung cancer.
INFLUENCE OF CELL TYPE AND STAGE ON
POST SURGICAL SURVIVAL–ERIC LIM
Malignant potential of neuroendocrine tumors are gov-
erned by stage (extent of disease) and grade (reflected by cell
type). If prognosis is determined predominantly by disease
extent then complete resection alone may suffice, neverthe-
less, if prognosis is determined predominantly by cell type,
then complete resection alone may be inadequate. Data from
the 177 patients in the Brompton Hospital cohort were pre-
sented, and Cox regression used to ascertain the joint influ-
ence of cell type and stage on survival. Although both
increasing stage and cell type were predictors of poorer
prognosis, on joint analysis, cell type had a stronger influence
on adverse survival. However, the two were not mutually
exclusive. As with most other surgical series from individual
centers, the numbers of events in general are small, nodal
involvement is relatively rare, therefore a clear answer can
only be obtained by the development and analysis of an
international registry.
PRIMARY CHEMOTHERAPY–BRITT SKOGSEID
Data from 61 patients treated for advanced bronchial
carcinoid tumors at Uppsala University were presented. The
overall 5 and 10 year survival from diagnosis was 70 and
48%, respectively. From the start of treatment, however, the
overall 5-year survival was 39%. For well differentiated
neuroendocrine tumors of the lung, there are no accepted
treatment regimens. At Uppsala University, the first line
treatment is Temozolomide and the second line is Streptozo-
tocin and doxorubicin or 5-florouracil (FU). Alternative reg-
imens include cisplatin and etoposide (1st line for poorly
differentiated tumors as assessed on Ki-67 index), biotherapy
(-interferon, somatostatin analogues), embolization, and ra-
diofrequency ablation. Temozolomide is an oral alkylating
agent that methylates guanine resulting in incorrect pairing
during DNA replication. Resistance to temozolomide is as-
sociated with high methyl guanine DNA methyltransferase
(MGMT) levels. Temozolomide was administered to 36 pa-
tients with advanced foregut tumors as third to fifth line therapy,
with 14% partial response and 53% with stable disease.12 A
prospective trial is required to establish the efficacy of this as
first line treatment. Results from Mirty et al.13 suggested that
cisplatin and etoposide was more efficacious in patients with
poorly differentiated tumors. There have been only few respond-
ers to streptozotocin and doxorubicin or 5-florouracil with stable
disease in approximately 25%.
ADJUVANT CHEMOTHERAPY–ERIC BAUDIN
The principles of adjuvant chemotherapy are to treat
patients with high risk of recurrence or death after complete
surgery to increase the disease-free and overall survival. At
present, there is little information to clearly define the risk of
recurrence and risk/benefit ratio of adjuvant therapy. As the
survival of typical carcinoids is excellent, and with concur-
rent chemo-radiotherapy being standard of care for small cell
lung carcinoma, the main focus of adjuvant chemotherapy is
on atypical carcinoid tumors and large cell neuroendocrine
carcinomas.
Large cell neuroendocrine carcinomas are heteroge-
neous tumors with a 5-year survival that is mainly dependant
on stage. Adverse markers of prognosis are mitoses more
than 37 per 10 high powered fields, a positive neuroendocrine
marker and the presence of metastatic disease.14 Of patients
who develop recurrences, 91% occur within the first 2 years
with 25 to 35% local recurrence and 50 to 56% distant
metastasis. Studies published from 1993 to 2006 have re-
ported partial or complete response to cisplatin based com-
binations rage from 41 to 78% in patients with stage III to IV
disease. A number of studies have reported 100% 5-year
survival with adjuvant and induction chemotherapy.15,16
Small-cell based chemotherapy has been reported to achieve
better results compared with nonsmall cell based regimens.17
There has also been a report of octreotide therapy to reduce
recurrence.18 Cisplatin and etoposide regimens have been
associated with excellent survival in stage I disease, but the
best regimen is still to be established. This strategy may not
be sufficient in stage II–III disease and combination radio-
therapy should be considered. Clearly a prospective random-
ized trial is required.
In general, the 5-year survival of patients with atypical
carcinoid tumors range are better in patients without lymph
node involvement compared with those with reported N1
disease. Significant difference in the outcome of this two
subgroups of patients has been observed recently.19 One
study reported the 5-year survival of patients with atypical
carcinoid with N2 disease to be 22%.20 Local and metastatic
recurrences occurs in 23%, respectively.21 There have been
too few reports to objectively assess the efficacy of adjuvant
chemotherapy, the target subset who would benefit and the
agent of choice. Atypical carcinoids with N2 disease are
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candidates for adjuvant therapy. The prognostic classification
for patients with atypical carcinoids and N1 disease needs to
be further evaluated.
MANAGEMENT OF ADVANCED
DISEASE–MARTYN CAPLIN
The SEER database has reported 13,715 cases of car-
cinoid tumors over the period 1973–1999, of which 25%
were of bronchopulmonary origin.22 The survival of pulmo-
nary carcinoid tumors is dependant on histologic grade with
10-year survival decreasing from 70 to 30 to 5% for low,
intermediate, and high grades, respectively.23 It is the practice
of the author to perform a biochemical profile for patients
with suspected neuroendocrine tumors. This includes mea-
surement of chromogranin A, urinary 5HIAA, peptide screen,
ACTH, and GHRH. In additional, one needs to consider
hereditary conditions such as MEN-1. Chromogranin A is
elevated in 58% and is related to tumor burden in gastroin-
testinal carcinoids.24 Image utilizing CT and/or MRI is used
for staging, however, the most sensitive modality for meta-
static disease is somatostatin receptor scintigraphy. Histo-
logic diagnosis is required in metastatic disease. The prog-
nostic indicators for carcinoid tumors include size, degree of
differentiation, proliferative index (Ki67)/mitotic index, pres-
ence of necrosis, cosecretion of peptides and metastases,
especially to the liver and bones. In patients with neuroen-
docrine tumors, surgery should be the main treatment option
if feasible. Symptomatic patients with residual disease should
be considered for a trial of somatostatin analogue therapy.
Asymptomatic patients with residual disease may be consid-
ered for an observation protocol or treatment utilizing soma-
tostatin analogue therapy or consideration of new agents such
as SOM230 and RAD001, however, this should be in the
context of a clinical trial. In patients who progress, there are
a number of other therapeutic options and these include:
chemotherapyzref25 (e.g., etoposide/cisplatin regimen; or
streptozotocin-based regimen or temozolomide regimen);
biotherapy (interferon or somatostatin) may be considered for
small volume diffuse disease in low grade tumor; radionu-
clide therapy (I131 MIBG, Y90 DOTA octreotide, or Lu177
octerotate) may be considered in patients who have positive
nuclear medicine imaging and patients may be considered for
trials of new agents (RAD001 an mTOR inhibitor, Bevaci-
zumab a vascular endothelial cell growth factor receptor
inhibitor and Sunitinib a multiple receptor tyrosin kinase
inhibitor). In patients with predominant hepatic disease
chemo-embolization,26,27 ablation therapy,28 and surgery29
can be considered. The evidence base for the management of
advanced bronchial neuroendocrine tumor is extremely lim-
ited and, therefore, patients should be seen in specialist NET
units and should be encouraged to participate in clinical trials.
RADIONUCLIDE THERAPY–DIK KWEKKEBOOM
For patients with inoperable neuroendocrine tumors, a
number of therapeutic options exist including somatostatin
analogues, -interferon, radiofrequency ablation, (chemo)
embolization, chemotherapy, and peptide receptor radionu-
clide therapy (PRRT). Radiolabeled somatostatin analogues
that can potentially be used for PRRT are listed in Table 4. At
Erasmus University, [177Lu-DOTA0,Tyr3]octreotate has been
used in patients with inoperable neuroendocrine tumors that
have proven uptake on Octreoscan, without prior therapy
with other radiolabeled somatostatin analogues.30 In practice,
amino acids are infused, followed by intravenous granisetron
and intravenous 177Lu-octreotate. This usually requires an
overnight stay. The maximum dose is based on bone marrow
and renal toxicity and is calculated individually (usually
between 600 and 800 mCi). Side effects include temporary
hair loss (62%), nausea (25%), vomiting (10%), and pain
(10%). Hormonal crisis are experienced in 1%, and may be
due to tumor lysis, discontinuation of somatostatin analogue
therapy, amino acids, or emotional stress. In the experience at
Erasmus University, all patients recovered with supportive
care (fluids, octreotide, corticosteroids, and correction of
acidosis and hypokalemia). In a series of 504 patients, there
was a 1% incidence of serious therapy-related complications
comprising of two patients who developed serious liver
toxicity and three who developed myelodysplastic syndrome.
For patients with bronchial carcinoids, 6/9 experienced re-
mission, with no differences between typical and atypical
subtypes, with an overall median survival of 31 months.31 In
general, there is further need for further validation and stan-
dardization of treatment. Randomized trials will be required
to compare efficacy. In general PRRT is associated with high
tumor response rate, limited side effects, good quality of life,
and relatively long progression free survival.
CURRENT AND NOVEL
BIOMARKERS–ELISABETH BRAMBILLA
The sensitivity and specificity of immunohistochemical
neuroendocrine tumor marker are listed in Table 5.32 Typical
and atypical carcinoid tumors tend to have positive neuroen-
docrine markers, with the following cytokeratin profile -
AE1-AE3 positive, KL1 positive, CK1,5,10,14 negative. In
addition, the tumors tend to be TTF-1 negative with a Ki-67
TABLE 4. Radiolabelled Somatostatin Analogues for Peptide
Receptor Therapy
111In-DTPA0octreotide
90Y-DOTA0,Tyr3octreotide
90Y-DOTA0lanreotide
177Lu-DOTA0,Tyr3octreotate
177Lu-DOTA0,Tyr3octreotide
90Y-DOTA0,Tyr3octreotate
TABLE 5. Discriminative Value of Neuroendocrine Markers
Marker Sensitivity (%) Specificity (%)
NSE 82 68
Leu7 39 97
Chromogranin 85 97
Synaptophysin 80 97
NCAM (CD56) 95 97
34E12 negative 95 95
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range between 3 and 15%, of which typical carcinoid tumors
tend to be 0 to 5% and atypical carcinoid tumors between 5
and 15%. Large cell neuroendocrine carcinoma expresses
tyrosine kinase receptors (c-kit 62%, SCF 47%, PDGF-R
60%, PDGF-R 82%, and Met 47%). In LCNEC and SCLC,
TTF-1 is expressed at variable levels but not amplified. The
p53 pathway is the central point of in the pathogenesis of
these tumors. Native p53 expression and p53 mutations
increase from no expression in typical carcinoids to high
expression in LCNEC and SCLC. As the tumor grade in-
creases, there are corresponding increases in the loss of Rb
gene expression (mutually exclusive to P16/CyclinD1 alter-
ations) with increased expression E2F1 expression and P14
losses. SKP2 and cyclin E are expressed in LCNEC and
SCLC and both increase with the grade of tumor. On the
whole, there is an apparent spectrum of low grade (typical
carcinoid) to intermediate grade (atypical carcinoid) to high
grade tumors (LCNEC and SCLC), but stem cell of origin
and absence of mixed carcinoid and high grade tumors
suggesting 2 different histogenesis patterns of these tumors
with typical and atypical carcinoids in one group and
LCNEC/SCLC in another.
BIOLOGIC THERAPY–BRITT SKOGSEID
Currently, -interferon and somatostatin analogues are
the two main forms of bio-therapy. The indications for use in
patients with carcinoid tumors are endocrine symptoms and
those in which chemotherapy is contraindicated. The princi-
ple mechanism for the action of -interferon is not yet
elucidated and a number of possible mechanisms have been
proposed (Table 6). In a meta-analysis involving 414 patients
with neuroendocrine tumors, clinical response was observed
in 32 to 53%, biochemical response in 39 to 49%, and tumor
response in 12 to 20%. There is also evidence supporting
improved survival in patients on continuous interferon ther-
apy compared with those that have stopped or received other
treatments. Specifically for bronchial carcinoid tumors, how-
ever, Granberg et al.33 reported that none of the 27 patients
demonstrated any tumor response to combination of -inter-
feron and somatostatin. Octreotide, however, remains an
important treatment modality for the management of carci-
noid crises. Other emerging treatment options include sor-
afenib and sunitinib. More work is required to evaluate
biologic agents in these rare diseases.
HISTORY AND BACKGROUND TO THE
INTERNATIONAL ASSOCIATION FOR THE
STUDY OF LUNG CANCER NEUROENDOCRINE
TUMORS REGISTRY–WILLIAM TRAVIS
The IASLC pathology panel met in 1995 to validate the
current pathologic classification of pulmonary neuroendo-
crine tumors, and over subsequent decades, discussion were
underway with Elisabeth Brambilla (Grenoble), Valerie
Rusch (MSKCC) and Bruce Johnson (Dana Farber). Initia-
tives for a registry were proposed at the neuroendocrine
symposium at the World Conference of Lung Cancer in
Barcelona in 2005 and several funding proposals were made
to the IASLC. In 2006 Peter Goldstraw (Brompton Hospital)
the chair of the IASLC staging committee was interested to
explore the TNM system in carcinoid tumors. Although data
from a large number of neuroendocrine tumors were received
in the IASLC staging project, there were a number of impor-
tant limitation, T factor details were limited, and subgroups
for detailed evaluation (e.g., multiple nodules, atelectasis,
pleural invasion) were lacking. It was also not possible to
differentiate between typical and atypical carcinoid tumors.
The establishment of an international registry is critical to
develop collaborations that allow for combining data on rare
neuroendocrine tumors, to encourage participation of existing
(Japan, Spain) registries, and the development of new national
registries. The aim would be to establish an international con-
sensus and a worldwide uniform approach for diagnosis, and
develop a tissue network for study of molecular changes with
hope of identifying molecular therapeutic targets.
THE IASLC NEUROENDOCRINE TUMORS
REGISTRY–PETER GOLDSTRAW
The IASLC Lung Cancer Staging Project collected data
on over 100,000 cases of lung cancer treated by all modalities
of care, between 1990 and 2000, from 46 Institutions in over
19 countries across the globe.34 After an initial sift, 81,015
cases were suitable for inclusion within their database. Of
these 67,725 cases were of NSCLC and analysis of these has
informed the revisions proposed for the forthcoming, 7th
edition of TNM for lung cancer.35–38
Within the database there were 13,290 cases of SCLC.
Analysis of these cases confirmed that the TNM classification
was appropriate for SCLC, including those cases being
treated by nonsurgical modalities.39 The database did not
specifically request data on carcinoid tumors as these have
previously been excluded from the TNM staging system.40,41
However, data was submitted on 518 carcinoid tumors
and analysis of these has suggested that TNM should be
applied to carcinoid tumors in the forthcoming, 7th edition of
TNM.42 The delineation of “atypical” and “typical” cases
were not reliable in this data and further cases will be
accumulated prospectively to confirm this suggestion. Large
cell neuroendocrine carcinoma (LCNEC) was only classified
as a distinct entity within the WHO classification in 1999.43
Therefore, there are very few such cases within the database.
The IASLC Lung Cancer Staging Project, therefore,
seeks to register additional neuroendocrine tumors. As funds
are limited it is necessary to be selective and discussion
TABLE 6. Possible Mechanisms for the Action of -Interferon
Stopping of the cell cycle from G0 to G1 phase
Induction of differentiation
Cytotoxicity
Increase MHC class I expression on tumor cells
Inhibition of growth factors or their receptor expression
Immune stimulation
Production of cytokines
Stromal changes
Anti-angiogenesis
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within the forum suggested that the following subgroups
should be prioritized:
a. Atypical carcinoid tumors.
b. Typical carcinoid tumors with nodal metastases.
c. LCNEC cases treated by all modalities of care, includ-
ing multimodality treatment.
The IASLC hope that the neuroendocrine registry can be used
to facilitate collaborative research, create virtual tissue bank
arrangements, and establish clinical study groups.
OVERVIEW OF THE REGISTRY TO
DATE–ERIC LIM
Over the course of the last three World Conferences on
Lung Cancer, Professor William Travis has been leading the
development of an international registry of pulmonary neu-
roendocrine tumors, and recently with the support of Profes-
sor Peter Goldstraw, the IASLC has limited funding for
support of the development of such a registry. A satellite
meeting was in at the World Conference of Lung Cancer in
Korea 2007, to obtain further international involvement, pub-
licity for the initiative and to establish resources for the
project. From the submissions of the participants in this
conference (in London) alone, we can see the number cases
available for study. This includes the two less common
subgroups—carcinoid tumors with nodal metastases and
medically treated patients. In addition, we now know that
many centers perform node sampling/dissection and bank
tissue samples. With limited resources, the international com-
munity need to decide on the subset of tumors in which data
should be collected for the retrospective and prospective
registries, the data fields and time frame in which this should
be achieved.
DATA COLLECTION AND SUBMISSION–
JOHN CROWLEY
CRAB stands for Cancer Research And Biostatistics,
and is a not-for-profit organization based in Seattle, USA.
Statistic projects run by CRAB include cancer clinical trials
for the US Southwest Oncology Group and with industry
partners. CRAB is also the statistics center of the IASLC
Staging Project and the Myeloma Institute for Research and
Therapy at the University of Arkansas for Medical Sciences.
The data fields associated with the IASLC International
Pulmonary Neuroendocrine Tumors Project are likely to be
based on the existing model used for submission of the
IASLC Staging Project.
(The rest of this presentation was based on a PDF of the
existing UICC lung cancer staging data fields.)
SUMMARY OF THE DISCUSSION
BY SURGEONS AND ONCOLOGISTS–
VALERIE RUSCH AND JAMES JETT
The surgeons and oncologists in the breakout session to
determine the scope and direction of the IASLC International
Pulmonary Neuroendocrine Tumors Project brought up a
number of questions. This includes the need to determine the
outcome of typical carcinoids with lymph node metastases,
the outcome of atypical carcinoid, LCNEC, and very early
SCLC (solitary pulmonary nodule) to determine if they rep-
resent a different population compared with the larger SCLC
population. There was interest in determining the incidence
of neuroendocrine tumors by subtype with time, differences
in the outcome of central and peripheral tumors, impact of
multiple tumor/tumorlets and if patients with recurrent dis-
ease have a different tumor characteristics. There was interest
in quantifying the incidence and types of associated paraneo-
plastic syndromes. The group believed that there was a lack
of studies on imaging characteristics, optimal staging path-
ways and characterization of the molecular features. The
group raised the awareness on the need to further evaluate the
role of serum markers in the diagnosis, staging, and clinical
management. It was generally agreed that more work is
required to determine the treatment options for patients with
advanced disease. There were suggestions to conduct a Phase
II trial of Temozolmide as first line treatment for patients with
metastatic bronchial carcinoid tumors, and a trial of adjuvant
therapy for completely resected LCNEC was of interest to the
participants.
SUMMARY OF THE DISCUSSION BY
PATHOLOGISTS–WILLIAM TRAVIS AND
ANDREW NICHOLSON
Issues raised in the breakout sessions by pathologists
were divided into retrospective and prospective issues and
included the following. Retrospectively, pathologists could
help focus on key rare subsets to study and central pathologic
review could be organized for entities such as typical carci-
noids with nodal and/or distant metastases, atypical carci-
noids, (LCNEC), and resected small cell carcinomas. Retro-
spectively, pathologic review should only be done for cases
with adequate clinical data. Prospectively, there is a need for
pathology review for problematic diagnoses such as LCNEC
in any therapeutic trials to ensure accurate patient selection.
This could be done regionally with specific leaders/reference
centers in each region. Prospectively, large cell carcinoma
with neuroendocrine morphology needs further study in re-
lationship to LCNEC. Prospectively, due to limited resources
in the process of development of an international registry,
only selective biomarker data would be submitted. Retrospec-
tively and prospectively, studies involving tumor microarray
are to be encouraged, but should be done locally (not glo-
bally). The final logistics for pathologic review needs to be
defined further once there is a clearer idea on the final number
of cases involved.
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